Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB41 vs Tislelizumab in First-Line Advanced NSCLC
NCT07662395Phase 3Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- May 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SCTB41 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoint: Progression-Free Survival at 24 months. Started May 2026; status: recruiting.
02
Drugs
SCTB41
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07662395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662395.